News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Janssen-Cilag International NV Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs
June 14, 2017
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
July 16, 2026
·
2 min read
·
Gabrielle Masson
Insights
The future of pain relief: Exploring opioid alternatives
July 16, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Lung cancer
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
July 15, 2026
·
2 min read
·
Michael Gibney
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
July 15, 2026
·
1 min read
·
Gabrielle Masson
